>>Description of the research protocol "Perjeta"

Medical Need Program: Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotheray for the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence defined as lymph node positive disease.
Phase MNP study| Status : Ongoing and recruiting

Additional details

Indication (or studied pathology) : Cancer du sein (Néo)adjuvant
Brugmann identifier : Perjeta


Involved department : Hemato-oncology
Principal investigator : Besse/Lecomte
Sponsor : Roche
Contact : Clinical Research Unit

>This protocol was approved by the UZA ethics committee.